Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Biomarcador de fertilización in vitro. Ensayo in vitro para detectar embriones con el potencial de implantación más alto para fertilización in vitro

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20160208001
Publicado:
23/02/2016
Caducidad:
23/02/2017
Resumen:
Laboratorios franceses buscan un socio industrial en el campo de salud reproductiva de la mujer con el fin de desarrollar y comercializar un nuevo biomarcador que permite la selección de embriones con el potencial de implantación más alto para fertilización in vitro. La tecnología satisface la necesidad de transferencia de un único embrión sin reducir la posibilidad de embarazo y evitando embarazos múltiples. Este biomarcador tiene el potencial de convertirse en el primer ensayo no invasivo empleado habitualmente en estos procesos. El objetivo es establecer acuerdos de licencia.

Details

Tittle:
In Vitro Fertilization (IVF) Biomarker - In vitro assay to screen embryos with the highest implantation potential for in vitro fertilization
Summary:
French laboratories are seeking an industrial partner in the women´s reproductive health to develop and market a novel biomarker (through a license agreement) permitting the selection of the embryos with the highest implantation potential for in vitro fertilization. The technology meets the need to transfer a unique embryo without minimizing the chance of pregnancy and avoiding multiple pregnancies. It has the potential to become the first non-invasive assay used in routine in such procedures.
Description:
Around 1 million in vitro fertilizations (IVF) are performed each year worldwide with a success rate of only 25%. To increase the chances, 2 or 3 embryos can be implanted, inducing a risk of multiple pregnancies for 20% of IVF that can cause an increased fetal mortality and maternal complications. Up to now, the embryo morphology evaluation is the only method of screening. A better prognosis assessment of implantation is needed in order to implant a single embryo without impacting the chances of pregnancy.

A French public research team from several laboratories involved in human health has identified a predictive biomarker helping to select the embryos showing the highest implantation potential.

They demonstrated that this soluble glycoprotein is a new factor regulating embryo implantation. The comparison of the concentration of this specific glycoprotein between 63 implanted vs.172 non-implanted embryos showed a significantly lower concentration in embryos that are implanted (p=0.0001).

The team is now looking for an industrial partner in the women´s reproductive health sector to develop and market this novel biomarker (through a license agreement).
Advantages and Innovations:
This glycoprotein could be a first-in-class predictive biomarker: no embryo biomarker has been developed so far contrary to various pre-implant biomarkers used for woman serum.

A reliable assay: any measure <1200 pg/ml of the biomarker is of good diagnosis. Taking into account the biomarker threshold, the research team obtained an increase of about 40% in IVF success.

A non-invasive assay: The biomarker is released in the culture supernatants of embryos.

An early biomarker: this is an early biomarker as it is already detected on day 2 after fertilization, which is compatible with a majority of medical centers specialized in IVF.

The biomarker´s concentration is independent of the morphology criteria. This predictive test should be used in routine for all embryos cultured for IVF.

Non-operator dependent procedure: Easy detection by enzyme-linked immunosorbent assay ELISA, a routine test to measure an unknown concentration of antigen, here the glycoprotein of interest.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority European patent application filed in April 2015.

Partner sought

Type and Role of Partner Sought:
The research team is currently looking for an industrial partner interested in licensing-in the technology.

In particular they are looking for a market player in women´s reproductive health (fertility, pregnancy and in vitro fertilization).

The objective is that the company develops and commercializes the first predictive kit for embryo selection in IVF.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06002007 Ensayos in vitro, experimentos
06001012 Investigaciones médicas
06001008 Medicina medioambiental, medicina social, medicina deportiva